| Patents for A61P 1 - Drugs for disorders of the alimentary tract or the digestive system (125,798) |
|---|
| 01/03/2003 | WO2002008187A9 Novel peptides as ns3-serine protease inhibitors of hepatitis c virus |
| 01/03/2003 | WO2002002603A3 Protein modification and maintenance molecules |
| 01/03/2003 | WO2001098468A3 Proteases |
| 01/03/2003 | WO2001098331A3 Glucagon-like peptide-1 analogs |
| 01/03/2003 | CA2459985A1 Pancam nucleic acids and polypeptides |
| 01/03/2003 | CA2455292A1 5-ht receptor ligands and uses thereof |
| 01/03/2003 | CA2452049A1 Uses of dc-sign and dc-signr for inhibiting hepatitis c virus infection |
| 01/03/2003 | CA2451686A1 A novel g protein-coupled receptor, gave 3 |
| 01/03/2003 | CA2451637A1 Liver engrafting cells, assays, and uses thereof |
| 01/03/2003 | CA2451271A1 Pancam nucleic acids and polypeptides |
| 01/03/2003 | CA2451138A1 Remedies for eosinophilic diseases |
| 01/03/2003 | CA2450969A1 Nucleic acid-associated proteins |
| 01/03/2003 | CA2450925A1 G-protein coupled receptors |
| 01/03/2003 | CA2450921A1 Protein modification and maintenance molecules |
| 01/03/2003 | CA2450579A1 Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| 01/03/2003 | CA2450562A1 Tyrosine kinase inhibitors |
| 01/03/2003 | CA2450550A1 Spiropiperidine compounds as ligands for orl-1 receptor |
| 01/03/2003 | CA2450491A1 5-ht receptor ligands and uses thereof |
| 01/03/2003 | CA2450478A1 Complex mixtures exhibiting selective inhibition of cyclooxygenase-2 |
| 01/03/2003 | CA2450475A1 Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| 01/03/2003 | CA2449844A1 Naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1) |
| 01/03/2003 | CA2447249A1 Abin-mediated hepatitis protection |
| 01/02/2003 | US20030004340 Skin disorders; gastrointestinal disorders |
| 01/02/2003 | US20030004324 31 human secreted proteins |
| 01/02/2003 | US20030004214 Irritable bowel disease |
| 01/02/2003 | US20030004211 Carbohydrate modifying agent and drinks containing the modifying agent |
| 01/02/2003 | US20030004196 Antiinflamamtory agents; autoimmune disease |
| 01/02/2003 | US20030004194 Method for treating fibrotic diseases or other indications VI |
| 01/02/2003 | US20030004193 Immunomodulators; antiinflammatory agents |
| 01/02/2003 | US20030004186 Anticoagulants; cardiovascular disorders; central nervous system disorders |
| 01/02/2003 | US20030004174 Antiinflammatory agents, anticancer agents, antihistamines, central nervous system disorders |
| 01/02/2003 | US20030004165 Polyazanaphthalene compounds and pharmaceutical use thereof |
| 01/02/2003 | US20030004164 Anticancer agents; autoimmune diseases |
| 01/02/2003 | US20030004163 Antiinflammatory agents; headaches; antiarthritic agents |
| 01/02/2003 | US20030004161 Anticancer agents; autoimmune diseases |
| 01/02/2003 | US20030004156 Anticholesterol agents; cardiovascular disorders; antidiabetic agents; antiproliferative agents |
| 01/02/2003 | US20030004153 Novel heteroaryl-diazabicycloalkanes |
| 01/02/2003 | US20030004151 Cyclic derivatives as modulators of chemokine receptor activity |
| 01/02/2003 | US20030004137 Muscle relaxants, controlling immunology, strokes, antidiabetic agents |
| 01/02/2003 | US20030004129 Formulations of adenosine a1 agonists |
| 01/02/2003 | US20030004126 Formulations of adenosine A1 agonists |
| 01/02/2003 | US20030004117 Methods for inhibiting angiogenesis |
| 01/02/2003 | US20030004110 Therapeutic compositions and methods for enhancing angiogenesis |
| 01/02/2003 | US20030004106 Interleukin-1 receptor antagonist-related molecules and uses thereof |
| 01/02/2003 | US20030003516 Therapeutic and diagnostic uses of antibody specificity profiles |
| 01/02/2003 | US20030003169 Prepared by fermenting an aqueous Glycine max (L.) extract with at least one lactic acid bacteria together with at least one yeast |
| 01/02/2003 | US20030003163 For restoration and maintenance of gingival and periodontal health; antiplaque/antitar agents; mouthwash |
| 01/02/2003 | US20030003105 Comprising lecithin and a polymer, preferably polyacrylic acid |
| 01/02/2003 | US20030003094 Compound which disrupts microtubule function and polymeric carrier, with proviso that polymeric carrier is not a capsule |
| 01/02/2003 | US20030003082 Use of poly-Glu,Tyr and T cells treated therewith for neuroprotective therapy |
| 01/02/2003 | US20030003077 A genetic engineered adenoviral vector contains an adenoviral genome from which the open reading frames E1 and/or E3 were deleted and a therapeutic gene or a DNA sequence that encodes for therapeutic proteins useful in fibrosis treatment |
| 01/02/2003 | US20030003058 Freeze-dried pantoprazole preparation and pantoprazole injection |
| 01/02/2003 | EP1270585A1 Peptide derivative |
| 01/02/2003 | EP1270569A1 Substituted tryptophan derivatives |
| 01/02/2003 | EP1270558A1 "Compound for the treatment of atherosclerotic-thrombotic pathological conditions" |
| 01/02/2003 | EP1270555A1 Method for oxidizing a thioether group into a sulfoxide group |
| 01/02/2003 | EP1270044A2 Wound healing biomarkers |
| 01/02/2003 | EP1269998A1 Composition of prolonged liberation in the form of multiple granules that enables the maintenance of the therapeutic action of 4-nitro-2-phenoximethanesulfonanilide |
| 01/02/2003 | EP1269990A1 Cosmetic or dermatological composition comprising acylaminoamide derivatives |
| 01/02/2003 | EP1269860A1 Pharmaceutical composition |
| 01/02/2003 | EP1269196A1 Method of screening for inhibitors of osteopontin |
| 01/02/2003 | EP1268854A1 High specificity marker detection |
| 01/02/2003 | EP1268802A2 Beta-like glycoprotein hormone polypeptide and heterodimer |
| 01/02/2003 | EP1268798A2 Anti-angiogenic and anti-tumor properties of vascostatin and other nidogen domains |
| 01/02/2003 | EP1268793A2 Fibroblast growth factor receptor-like molecules and uses thereof |
| 01/02/2003 | EP1268784A2 Genes involved in intestinal inflammatory diseases and use thereof |
| 01/02/2003 | EP1268783A2 Anti-angiogenic and anti-tumor properties of matin and other laminin domains |
| 01/02/2003 | EP1268781A2 G12l, a gene associated with the thermal response |
| 01/02/2003 | EP1268775A1 The high bone mass gene of 11q13.3 |
| 01/02/2003 | EP1268768A2 Targeted chromosomal genomic alterations with modified single stranded oligonucleotides |
| 01/02/2003 | EP1268554A2 Diagnostic and medicament for analysing the cell surface proteome of tumour and inflammatory cells and for treating tumorous and inflammatory diseases, preferably using a specific chemokine receptor analysis and the chemokine receptor-ligand interaction |
| 01/02/2003 | EP1268553A1 Use of cd25 binding molecules in the treatment of inflammatory diseases of the gastro-intestinal tract |
| 01/02/2003 | EP1268549A2 Method of identifying inhibitors of tie-2 |
| 01/02/2003 | EP1268530A1 Hepatitis b core antigen fusion proteins |
| 01/02/2003 | EP1268495A1 Sulfur substituted aryldifluoromethylphosphonic acids as ptp-1b inhibitors |
| 01/02/2003 | EP1268494A1 Sulfur substituted aryldifluoromethylphosphonic acids as ptp-1b inhibitors |
| 01/02/2003 | EP1268489A1 Dihydroimidazo[2,1-b]thiazole and dihydro-5h-thiazolo[3,2-a]pyrimidines as antidepressant agents |
| 01/02/2003 | EP1268487A1 Tricyclic protein kinase inhibitors |
| 01/02/2003 | EP1268484A1 Condensed imidazoles as histamine h3 receptor ligands |
| 01/02/2003 | EP1268483A1 Condensed imidazoles as histamine h3 receptor ligands |
| 01/02/2003 | EP1268481A2 Kinase inhibitors as therapeutic agents |
| 01/02/2003 | EP1268480A1 8-quinolinxanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors |
| 01/02/2003 | EP1268471A1 N-heterocyclic derivatives as nos inhibitors |
| 01/02/2003 | EP1268465A1 Triarylimidazole derivatives as cytokine inhibitors |
| 01/02/2003 | EP1268455A2 Piperazine derivatives |
| 01/02/2003 | EP1268448A1 Bicyclic amine derivatives as inhibitors of class 1 receptor tyrosine kinases |
| 01/02/2003 | EP1268437A1 Inhibitors of protein kinases |
| 01/02/2003 | EP1268435A1 4,5-dihydro-1h-pyrazole derivatives having cb 1-antagonistic activity |
| 01/02/2003 | EP1268431A1 3-cyanoquinolines,3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors |
| 01/02/2003 | EP1268430A1 Chemical complex compprising a pyridine carboxy derivative and an h2 histamine receptor antagonist |
| 01/02/2003 | EP1268419A1 Pyrrolidine derivatives useful as bax inhibitors |
| 01/02/2003 | EP1268418A1 Pharmaceutically active pyrrolidine derivatives as bax inhibitors |
| 01/02/2003 | EP1268407A1 Propenecarboxylic acid amidoxime derivatives, a process for the preparation thereof, and pharmaceutical compositions containing the same |
| 01/02/2003 | EP1268393A2 Lipoxin analogs and methods for the treatment of periodontal disease |
| 01/02/2003 | EP1268305A1 Infusion packet with useful and decorative elements, support member, delivery system and method |
| 01/02/2003 | EP1267954A1 Medical devices suitable for gene therapy regimens |
| 01/02/2003 | EP1267931A1 Rhodamine derivatives for photodynamic diagnosis and treatment |
| 01/02/2003 | EP1267915A2 Methods of treating diseases with activated protein c |
| 01/02/2003 | EP1267912A2 Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility |
| 01/02/2003 | EP1267899A2 Salmonella vaccine materials and methods |